Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 22,527,000	$ 17,166,000
General and administrative	12,113,000	9,820,000
Loss from operations	(34,640,000)	(26,986,000)
Other income (expenses), net:
Interest expense	(1,618,000)	(1,282,000)
Interest income and other income (expenses), net	549,000	(34,000)
Total other income (expenses), net	(1,069,000)	(1,316,000)
Provision for income taxes	0	0
Net loss	$ (35,709,000)	$ (28,302,000)
Net loss per share of common stock and pre-funded warrants, basic	$ (3.09)	$ (7.47)
Net loss per share of common stock and pre-funded warrants, diluted	$ (3.09)	$ (7.47)
Weighted-average shares of common stock and pre-funded warrants outstanding, basic	11,548,907	3,790,303
Weighted-average shares of common stock and pre-funded warrants outstanding, diluted	11,548,907	3,790,303